Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 5—May 2021
Research Letter

COVID-19 Co-infection with Legionella pneumophila in 2 Tertiary-Care Hospitals, Germany

Hedda L. VerhasseltComments to Author , Jan Buer, Jutta Dedy, Renate Ziegler, Joerg Steinmann, Frank Herbstreit, Thorsten Brenner, and Peter-Michael Rath
Author affiliations: University of Duisburg-Essen, Essen, Germany (H.L. Verhasselt, J. Buer, J. Dedy, F. Herbstreit, T. Brenner, P.-M. Rath); Paracelsus Medical University, Nuremberg, Germany (R. Ziegler, J. Steinmann)

Main Article

Table

Demographics and underlying conditions of patients with COVID-19 examined for Legionella pneumophila urine antigen, Germany

Characteristic Value
Total 93 (100.0)
Negative for L. pneumophila serogroup 1 antigen 92 (98.9)
Positive for L. pneumophila serogroup 1 antigen
1 (1.1)
Average time between admission and Legionella antigen test processing 2.6 d (mean), 1 d (median)
Legionella-specific culture† performed/positive 18 (19.4)/0
Legionella nonspecific culture performed/positive 35 (37.6)/11 (31.4)
Multiplex PCR‡ performed/positive 31 (33.3)/5 (16.1)
Clinical symptoms typical for COVID-19§
60 (90.0)
Hospitalized 93 (100)
Transferred from other hospital 35 (37.6)
Treated in intensive care unit
40 (43.0)
Mean age, years
65
Sex
M 66 (71.0)
F
27 (29.0)
Invasive mechanical ventilation 36 (38.7)
Extracorporeal membrane oxygenation 17 (18.3)
Mortality
30 (32.3)
Underlying conditions
Cardiovascular disease 50 (53.8)
Diabetes 28 (30.1)
Chronic respiratory disease 13 (14.0)
Cancer 10 (11.0)
Other: rheumatism, Parkinson's disease 17 (18.3)
Addictions: alcohol, nicotine 7 (7.5)
Solid organ transplantation: lung 1 (1.1)
None 15 (16.1)
1 underlying condition 55 (59.1)
2 underlying conditions 29 (31.2)
>2 underlying conditions 7 (7.5)

*Values are no. (%) except as indicated.
†Legionella BMPA selective agar (Thermo Scientific, https://www.thermofisher.com). 
‡Unyvero P50 pneumonia application (Curetis GmbH, https://curetis.com) or ampliCube Respiratory Panel 1 (Mikrogen Diagnostic, https://www.mikrogen.de).
§Data available for 67 patients.

Main Article

Page created: April 05, 2021
Page updated: April 21, 2021
Page reviewed: April 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external